336 related articles for article (PubMed ID: 18823367)
1. The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain.
Sanderson L; Dogruel M; Rodgers J; Bradley B; Thomas SA
J Neurochem; 2008 Nov; 107(4):1136-46. PubMed ID: 18823367
[TBL] [Abstract][Full Text] [Related]
2. The distribution of nifurtimox across the healthy and trypanosome-infected murine blood-brain and blood-cerebrospinal fluid barriers.
Jeganathan S; Sanderson L; Dogruel M; Rodgers J; Croft S; Thomas SA
J Pharmacol Exp Ther; 2011 Feb; 336(2):506-15. PubMed ID: 21057057
[TBL] [Abstract][Full Text] [Related]
3. Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein.
Sanderson L; Dogruel M; Rodgers J; De Koning HP; Thomas SA
J Pharmacol Exp Ther; 2009 Jun; 329(3):967-77. PubMed ID: 19261919
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance in human African trypanosomiasis.
Barrett MP; Vincent IM; Burchmore RJ; Kazibwe AJ; Matovu E
Future Microbiol; 2011 Sep; 6(9):1037-47. PubMed ID: 21958143
[TBL] [Abstract][Full Text] [Related]
5. Current chemotherapy of human African trypanosomiasis.
Docampo R; Moreno SN
Parasitol Res; 2003 Jun; 90 Supp 1():S10-3. PubMed ID: 12811544
[TBL] [Abstract][Full Text] [Related]
6. Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Steverding D; Rushworth SA
Exp Parasitol; 2017 Jul; 178():45-50. PubMed ID: 28552794
[TBL] [Abstract][Full Text] [Related]
7. Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
Dauchy FA; Bonhivers M; Landrein N; Dacheux D; Courtois P; Lauruol F; Daulouède S; Vincendeau P; Robinson DR
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005125. PubMed ID: 27855164
[TBL] [Abstract][Full Text] [Related]
8. Delivery of antihuman African trypanosomiasis drugs across the blood-brain and blood-CSF barriers.
Sekhar GN; Watson CP; Fidanboylu M; Sanderson L; Thomas SA
Adv Pharmacol; 2014; 71():245-75. PubMed ID: 25307219
[TBL] [Abstract][Full Text] [Related]
9. The treatment of human African trypanosomiasis.
Pépin J; Milord F
Adv Parasitol; 1994; 33():1-47. PubMed ID: 8122565
[No Abstract] [Full Text] [Related]
10. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
Jansson-Löfmark R; Na-Bangchang K; Björkman S; Doua F; Ashton M
Antimicrob Agents Chemother; 2015 Feb; 59(2):1299-307. PubMed ID: 25512417
[TBL] [Abstract][Full Text] [Related]
11. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
[TBL] [Abstract][Full Text] [Related]
12. Eflornithine for the treatment of human African trypanosomiasis.
Burri C; Brun R
Parasitol Res; 2003 Jun; 90 Supp 1():S49-52. PubMed ID: 12811548
[TBL] [Abstract][Full Text] [Related]
13. Anti-sleeping sickness drugs and cancer chemotherapy.
Barrett SV; Barrett MP
Parasitol Today; 2000 Jan; 16(1):7-9. PubMed ID: 10637579
[No Abstract] [Full Text] [Related]
14. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
[TBL] [Abstract][Full Text] [Related]
15. DL-alpha-difluoromethylornithine (DFMO)-Berenil combination: therapeutic and prophylactic activity against Trypanosoma brucei brucei infection in mice.
Onyeyili PA; Egwu GO; Zaria LT; Orjiude BA
Rev Elev Med Vet Pays Trop; 1991; 44(4):443-5. PubMed ID: 1843826
[TBL] [Abstract][Full Text] [Related]
16. African sleeping sickness.
Hedley L; Fink D; Sparkes D; Chiodini PL
Br J Hosp Med (Lond); 2016 Oct; 77(10):C157-C160. PubMed ID: 27723399
[No Abstract] [Full Text] [Related]
17. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
[TBL] [Abstract][Full Text] [Related]
18. Studies on lipidomimetic derivatives of alpha-difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma B. brucei murine trypanosomiasis model.
Loiseau PM; Czok M; Chauffert O; Bourass J; Letourneux Y
Parasite; 1998 Sep; 5(3):239-46. PubMed ID: 9772723
[TBL] [Abstract][Full Text] [Related]
19. [Action of drugs tested in an acellular medium and in mice infected with Trypanosoma brucei brucei].
Bouteille B; Darde ML; Pestre-Alexandre M
Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):533-42. PubMed ID: 3143489
[TBL] [Abstract][Full Text] [Related]
20. A new nonpolar N-hydroxy imidazoline lead compound with improved activity in a murine model of late-stage Trypanosoma brucei brucei infection is not cross-resistant with diamidines.
Ríos Martínez CH; Miller F; Ganeshamoorthy K; Glacial F; Kaiser M; de Koning HP; Eze AA; Lagartera L; Herraiz T; Dardonville C
Antimicrob Agents Chemother; 2015 Feb; 59(2):890-904. PubMed ID: 25421467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
